Scarica l'app Stockscreener
27.80
0.91%
0.25
Dopo l'orario di chiusura:
27.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$27.55
Aprire:
$27.83
Volume 24 ore:
741.99K
Relative Volume:
0.37
Capitalizzazione di mercato:
$2.56B
Reddito:
$490.73M
Utile/perdita netta:
$-50.26M
Rapporto P/E:
-46.10
EPS:
-0.603
Flusso di cassa netto:
$-20.37M
1 W Prestazione:
+2.06%
1M Prestazione:
-0.07%
6M Prestazione:
+18.45%
1 anno Prestazione:
+45.32%
Intervallo 1D:
$26.95
$28.58
Intervallo di 1 settimana:
$26.90
$29.48
Portata 52W:
$12.91
$42.13
Travere Therapeutics Inc Stock (TVTX) Company Profile
Nome
Travere Therapeutics Inc
Settore
Industria
Telefono
888-969-7879
Indirizzo
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
27.80 | 2.56B | 490.73M | -50.26M | -20.37M | -0.603 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-09 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-12-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-20 | Iniziato | Citigroup | Neutral |
| 2023-09-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Ripresa | Evercore ISI | Outperform |
| 2023-07-21 | Iniziato | JP Morgan | Overweight |
| 2023-06-07 | Ripresa | Piper Sandler | Neutral |
| 2023-05-22 | Iniziato | TD Cowen | Outperform |
| 2023-05-05 | Aggiornamento | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-21 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-12-14 | Iniziato | Stifel | Hold |
| 2022-12-05 | Iniziato | Wells Fargo | Overweight |
| 2022-09-21 | Iniziato | Bryan Garnier | Sell |
| 2022-07-14 | Ripresa | Canaccord Genuity | Buy |
| 2022-03-31 | Iniziato | Piper Sandler | Overweight |
| 2022-02-28 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-26 | Downgrade | Wedbush | Outperform → Neutral |
Mostra tutto
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
How Investors Are Reacting To Travere Therapeutics (TVTX) FILSPARI Momentum And Mirum Milestone Windfall - simplywall.st
Understanding the Setup: (TVTX) and Scalable Risk - Stock Traders Daily
How liquid is Travere Therapeutics Inc. stockProfit Target & Smart Investment Allocation Insights - mfd.ru
Piper Sandler Increases Target Price for Travere Therapeutics (TVTX) - Finviz
Assessing Travere Therapeutics (TVTX) Valuation After FILSPARI Sales Momentum And Expected Mirum Milestone Payment - Sahm
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Kentucky Teachers Retirement System Invests $732,000 in Travere Therapeutics - National Today
Travere Therapeutics, Inc. $TVTX Shares Sold by GW&K Investment Management LLC - MarketBeat
Published on: 2026-03-07 06:27:27 - baoquankhu1.vn
Royce & Associates Reduces Stake in Travere Therapeutics - National Today
Royce & Associates LP Reduces Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Vanguard Group Inc. Has $158.06 Million Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Exploring a 44.65% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Legato Capital Management LLC Acquires Shares of 71,030 Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
TVTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Total debt per share of Travere Therapeutics, Inc. – BOATS:TVTX - TradingView
Travere Therapeutics (TVTX) Is Up 7.4% After FILSPARI-Fueled Revenue Surge And Narrower LossesHas The Bull Case Changed? - simplywall.st
Travere Therapeutics, Inc. (TVTX) Stock Analysis: A 39% Upside Potential Sparks Investor Interest - DirectorsTalk Interviews
Travere Therapeutics (TVTX) CEO sells 60,000 shares in 10b5-1 trade - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM) - The Globe and Mail
Travere Therapeutics, Inc. (TVTX): A Bull Case Theory - Finviz
Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 - Finviz
Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms (NASDAQ:TVTX) - Seeking Alpha
A Look At Travere Therapeutics (TVTX) Valuation After Q4 Earnings Beat And FILSPARI Regulatory Progress - Yahoo Finance
Assessing Travere Therapeutics (TVTX) Valuation After Strong Earnings Beat And Pipeline Progress - simplywall.st
Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to Buy - MarketBeat
Analysts Offer Insights on Healthcare Companies: Integra Lifesciences (IART) and Travere Therapeutics (TVTX) - The Globe and Mail
Travere outlines FILSPARI-driven growth and new FSGS milestone as 2026 begins - MSN
Travere Therapeutics Earnings Call Shows Growth Amid Risks - TipRanks
TVTX (NASDAQ): Affiliate files Form 144 to sell 60,000 shares - Stock Titan
Travere Therapeutics (NASDAQ:TVTX) Shares Down 5.4%Should You Sell? - MarketBeat
Travere Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Highlights - GuruFocus
Decoding Travere Therapeutics Inc (TVTX): A Strategic SWOT Insig - GuruFocus
Travere Therapeutics Q4 Earnings Call Highlights - MarketBeat
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
TVTX: FILSPARI drove record revenue and patient growth in 2025, with strong outlook for 2026 - TradingView
Travere (TVTX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates - Yahoo Finance
Travere Therapeutics, Inc. SEC 10-K Report - TradingView
TVTX: 2025 revenue surged to $490.7M on FILSPARI growth; net loss narrowed and pipeline advanced - TradingView
Travere Therapeutics (NASDAQ:TVTX) Announces Quarterly Earnings Results, Beats Estimates By $0.42 EPS - MarketBeat
Travere Therapeutics posts surprise Q4 profit; Shares slip 5% on revenue miss - Investing.com Canada
Travere: Fourth Quarter Financial Results Overview - Bitget
Travere: Q4 Earnings Snapshot - KVUE
Earnings Flash (TVTX) Travere Therapeutics, Inc. Posts Q4 Adjusted EPS $0.37 per Share, vs. FactSet Est of $0.38 - marketscreener.com
FILSPARI surge drives Travere Therapeutics (TVTX) to 2025 non-GAAP profit - Stock Titan
Travere Therapeutics Q4 Earnings Report: What Investors Need to Know - Benzinga
Travere Therapeutics Inc Azioni (TVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):